Endocrine-Related Cancer ( 2003 ) 10 179 – 186 International Congress on Hormonal Steroids and Hormones and Cancer Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells

The central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progression have resulted in significant advances in understanding these links. Estrogens independently regulate the expression and function of c-Myc and cyclin D1 and the induction of either c-Myc or cyclin D1 is sufficient to recapitulate the effects of estrogen on cell cycle progression. These pathways converge at the activation of cyclin E–Cdk2 complexes. The active cyclin E–Cdk2 complexes are depleted of the cyclin dependent kinase (CDK) inhibitor p21 because of estrogen-mediated inhibition of nascent p21. Insulin and estrogen synergistically stimulate cell cycle progression, and the ability of estrogen to antagonize an insulin-induced increase in p21 gene expression appears to underlie this effect. Antiestrogen treatment of MCF-7 cells leads to an acute decrease of c-Myc expression, a subsequent decline in cyclin D1, and ultimately arrest of cells in a state with features characteristic of quiescence. An antisense-mediated decrease in c-Myc expression results in decreased cyclin D1 expression and inhibition of DNA synthesis, mimicking the effects of antiestrogen treatment and emphasizing the importance of c-Myc as an estrogen/antiestrogen target. These data identify c-Myc, cyclin D1, p21 and cyclin E-Cdk2 as central components of estrogen regulation of cell cycle progression and hence as potential downstream targets that contribute to the role of estrogen in oncogenesis. Endocrine-Related Cancer (2003) 10 179–186

[1]  R. Sutherland,et al.  Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI‐277 on inhibition of MCF‐7 breast cancer cell‐cycle progression , 2003, International journal of cancer.

[2]  J. Carroll,et al.  Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. , 2003, Endocrinology.

[3]  G. Alton,et al.  Identification of a Structural Determinant , 2002 .

[4]  J. Carroll,et al.  Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. , 2002, Cancer research.

[5]  Chi-Wai Wong,et al.  Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Chris Albanese,et al.  Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression* , 2002, The Journal of Biological Chemistry.

[7]  A. Cato,et al.  Rapid Actions of Steroid Receptors in Cellular Signaling Pathways , 2002, Science's STKE.

[8]  J. Carroll,et al.  Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. , 2002, Cancer research.

[9]  Donald P. McDonnell,et al.  Connections and Regulation of the Human Estrogen Receptor , 2002, Science.

[10]  F. Orr,et al.  C‐myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells , 2002, International journal of cancer.

[11]  Steven F. Dowdy,et al.  Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes , 2002 .

[12]  L. Penn,et al.  The myc oncogene: MarvelouslY Complex. , 2002, Advances in cancer research.

[13]  Hans Clevers,et al.  The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. , 2002, Cell.

[14]  J. Carroll,et al.  A Low Abundance Pool of Nascent p21WAF1/Cip1 Is Targeted by Estrogen to Activate Cyclin E·Cdk2* , 2001, The Journal of Biological Chemistry.

[15]  J. Slingerland,et al.  Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[16]  S. Johnston,et al.  Farnesyl transferase inhibitors--a novel therapy for breast cancer. , 2001, Endocrine-related cancer.

[17]  S. Safe,et al.  Estrogen Regulation of Cyclin D1 Gene Expression in ZR-75 Breast Cancer Cells Involves Multiple Enhancer Elements* , 2001, The Journal of Biological Chemistry.

[18]  Antonin Bukovsky,et al.  Multifaceted Regulation of Cell Cycle Progression by Estrogen: Regulation of Cdk Inhibitors and Cdc25A Independent of Cyclin D1-Cdk4 Function , 2001, Molecular and Cellular Biology.

[19]  J. Carroll,et al.  A Low Abundance Pool of Nascent p21 Is Targeted by Estrogen to Activate Cyclin E Cdk2* , 2001 .

[20]  J. Carroll,et al.  A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence* , 2000, The Journal of Biological Chemistry.

[21]  S. Cariou.  Down-regulation of p21^ or p27^ abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells , 2000 .

[22]  J. Slingerland,et al.  Down-regulation of p 21 WAF 1 y CIP 1 or p 27 Kip 1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells , 2000 .

[23]  J. Mester,et al.  Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[25]  N. Rosen,et al.  A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells* , 1998, The Journal of Biological Chemistry.

[26]  R. Sutherland,et al.  c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry , 1998, Molecular and Cellular Biology.

[27]  F. Lallemand,et al.  Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. , 1998, Cancer research.

[28]  V. Moudgil,et al.  Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells , 1997, Oncogene.

[29]  R. Weinberg,et al.  Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution , 1997, Molecular and cellular biology.

[30]  R. Sutherland,et al.  Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  R. Sutherland,et al.  Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* , 1997, The Journal of Biological Chemistry.

[32]  J. Bartek,et al.  Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint , 1996, Molecular and cellular biology.

[33]  J. S. Foster,et al.  Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. , 1996, Molecular endocrinology.

[34]  N. Hay,et al.  p21 Disrupts the interaction between cdk2 and the E2F-p130 complex , 1996, Molecular and cellular biology.

[35]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[36]  M. Eilers,et al.  Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts. , 1995, Oncogene.

[37]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[38]  L. M. Facchini,et al.  Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. , 1994, Oncogene.

[39]  M. Pagano,et al.  Differential modulation of cyclin gene expression by MYC. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Shiu,et al.  Mechanism of estrogen activation of c-myc oncogene expression. , 1992, Oncogene.

[41]  P. Watson,et al.  Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. , 1991, Cancer research.

[42]  R. Sutherland,et al.  Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. , 1989, Cancer research.

[43]  M. Blankenstein,et al.  Mitogenic stimulation of human breast cancer cells in a growth factor‐defined medium: Synergistic action of insulin and estrogen , 1988, Journal of cellular physiology.

[44]  R. Shiu,et al.  Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. , 1987, Cancer research.

[45]  B. Leung,et al.  Mode of estrogen action on cell proliferation in CAMA‐1 cells: II. Sensitivity of G1 phase population , 1987, Journal of cellular biochemistry.

[46]  L. Murphy,et al.  Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. , 1987, Endocrinology.

[47]  C. Osborne,et al.  Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. , 1984, Cancer research.

[48]  I. Taylor,et al.  Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. , 1983, Cancer research.

[49]  I W Taylor,et al.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. , 1983, Cancer research.

[50]  C. Osborne,et al.  Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. , 1983, Cancer research.